The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology

Wasniewski,Tomasz; Woclawek-Potocka,Izabela; Boruszewska,Dorota; Kowalczyk-Zieba,Ilona; Sinderewicz,Emilia; Grycmacher,Katarzyna

doi:10.3892/or.2015.4216

The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology

Authors:
- Tomasz Wasniewski
- Izabela Woclawek-Potocka
- Dorota Boruszewska
- Ilona Kowalczyk-Zieba
- Emilia Sinderewicz
- Katarzyna Grycmacher
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Warmia and Masuria, 10-561 Olsztyn, Poland, Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-747 Olsztyn, Poland
Published online on: August 20, 2015 https://doi.org/10.3892/or.2015.4216
Pages: 2760-2767

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to study lysophosphatidic acid (LPA) signaling associated with type 1 endometrial carcinoma (EC), we evaluated the LPA receptors (LPARs), autotaxin (ATX) and phospholipase A2 (PLA2) expression in EC and normal endometrium with correlation to clinicopathological features. We investigated LPAR1, LPAR2, LPAR3, LPAR4, ATX and PLA2 expression at mRNA and protein levels using quantitative real-time PCR and western blot analyses in 37 ECs and 10 normal endometria. All the examined LPARs (except for LPAR3 protein), ATX and PLA2 were overexpressed in cancerous compared to healthy endometrium. The studied ECs showed the highest LPAR2 and LPAR1 expression. Statistically positive correlations were found between depth of myoinvasion and levels of LPAR1, LPAR2 and PLA2 transcripts and proteins. We also found positive correlations between LPAR1, LPAR2, LPAR4 and PLA2 expression with the International Federation of Gynecology and Obstetrics (FIGO) stage. The expression of LPAR1, LPAR2 and PLA2 was positively associated with the age of patients. Positive correlations were found between the expression of LPAR1 mRNA, LPAR2 mRNA and protein and LPAR3 mRNA and body mass index (BMI) of the examined patients. We found no association between the expression levels of the studied factors and diabetes or hypertension among the examined patients. Owing to the highest LPAR2 and LPAR1 expression in EC and positive correlations of these two receptors with the depth of myoinvasion and the FIGO stage, we believe that LPAR2 and LPAR1 show promise as predictors of the EC progression as well as the main receptors responsible for LPA action in the EC tissue.

View Figures

View References

1	Didkowska J, Wojciechowska U, Tarkowski W and Zatoński W: Cancer in Poland in 2009. Polish National Cancer Registry. Department of Epidemiology and Cancer Prevention. The Maria Skłodowska-Curie Memorial Cancer Center; Warsaw: 2011
2	Schouten LJ, Goldbohm RA and van den Brandt PA: Anthropometry, physical activity, and endometrial cancer risk: Results from the Netherlands Cohort Study. J Natl Cancer Inst. 96:1635–1638. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
4	Parazzini F, La Vecchia C, Bocciolone L and Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol. 41:1–16. 1991. View Article : Google Scholar : PubMed/NCBI
5	Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al: Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 88:1127–1135. 1996. View Article : Google Scholar : PubMed/NCBI
6	Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M, Mittal KR, Raju U, Banerjee S, et al: Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study. Br J Cancer. 84:975–981. 2001. View Article : Google Scholar : PubMed/NCBI
7	Park CK, Apte S, Acs G and Harris EER: Cancer endometrium. Abeloff's Clinical Oncology. Abeloff M, Armitage J, Niederhuber J, Kastan M and McKenna W: 4th edition. Elsevier; Philadelphia: 2008, View Article : Google Scholar
8	Ye X and Chun J: Lysophosphatidic acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol Metab. 21:17–24. 2010. View Article : Google Scholar :
9	Aoki J: Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol. 15:477–489. 2004. View Article : Google Scholar : PubMed/NCBI
10	Okudaira S, Yukiura H and Aoki J: Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 92:698–706. 2010. View Article : Google Scholar : PubMed/NCBI
11	Billon-Denis E, Tanfin Z and Robin P: Role of lysophosphatidic acid in the regulation of uterine leiomyoma cell proliferation by phospholipase D and autotaxin. J Lipid Res. 49:295–307. 2008. View Article : Google Scholar
12	Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K and Fishman DA: LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol. 112:215–223. 2009. View Article : Google Scholar
13	Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA, Smith PJ and Fishman DA: Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 117:88–95. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhao S and Fernald RD: Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol. 12:1047–1064. 2005. View Article : Google Scholar : PubMed/NCBI
15	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
16	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
17	Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, et al: Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol. 358:244–255. 2012. View Article : Google Scholar
18	Jereczek-Fossa B, Badzio A and Jassem J: Surgery followed by radiotherapy in endometrial cancer: Analysis of survival and patterns of failure. Int J Gynecol Cancer. 9:285–294. 1999. View Article : Google Scholar
19	Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M and Casey G: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 280:719–723. 1998. View Article : Google Scholar : PubMed/NCBI
20	Shen Z, Belinson J, Morton RE and Xu Y and Xu Y: Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol. 71:364–368. 1998. View Article : Google Scholar
21	Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, et al: Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci. 905:188–208. 2000. View Article : Google Scholar : PubMed/NCBI
22	Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, et al: LPA receptors: Subtypes and biological actions. Annu Rev Pharmacol Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
23	Xiao Y, Chen Y, Kennedy AW, Belinson J and Xu Y: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann NY Acad Sci. 905:242–259. 2000. View Article : Google Scholar : PubMed/NCBI
24	Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J and Xu Y: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 290:302–313. 2001. View Article : Google Scholar : PubMed/NCBI
25	Yoon HR, Kim H and Cho SH: Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 788:85–92. 2003. View Article : Google Scholar : PubMed/NCBI
26	Goetzl EJ, Kong Y and Mei B: Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol. 162:2049–2056. 1999.PubMed/NCBI
27	Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, et al: Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res. 5:4308–4318. 1999.
28	Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X and Mills GB: Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 100:1630–1642. 2008. View Article : Google Scholar : PubMed/NCBI
29	Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N and Jaffe RB: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 93:762–768. 2001. View Article : Google Scholar : PubMed/NCBI
30	Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E and Nakano H: Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 192:161–169. 2003. View Article : Google Scholar : PubMed/NCBI
31	Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M: Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
32	Crosbie EJ, Zwahlen M, Kitchener HC, Egger M and Renehan AG: Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 19:3119–3130. 2010. View Article : Google Scholar : PubMed/NCBI
33	Everett E, Tamimi H, Greer B, Swisher E, Paley P, Mandel L and Goff B: The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 90:150–157. 2003. View Article : Google Scholar : PubMed/NCBI
34	Martra F, Kunos C, Gibbons H, Zola P, Galletto L, DeBernardo R and von Gruenigen V: Adjuvant treatment and survival in obese women with endometrial cancer: An international collaborative study. Am J Obstet Gynecol. 198:89.e1–89.e8. 2008. View Article : Google Scholar
35	Münstedt K, Wagner M, Kullmer U, Hackethal A and Franke FE: Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control. 19:909–916. 2008. View Article : Google Scholar : PubMed/NCBI
36	Litta P, Di Giuseppe J, Moriconi L, Delli Carpini G, Piermartiri MG and Ciavattini A: Predictors of malignancy in endometrial polyps: A multi-institutional cohort study. Eur J Gynaecol Oncol. 35:382–386. 2014.PubMed/NCBI
37	Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Levitt J, Girda E, Goldfinger M, Goldberg GL and Einstein MH: Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol. 124:300–306. 2014. View Article : Google Scholar : PubMed/NCBI